Balchem Corp Announces Executive and Director Changes
Ticker: BCPC · Form: 8-K · Filed: Feb 14, 2025 · CIK: 9326
| Field | Detail |
|---|---|
| Company | Balchem CORP (BCPC) |
| Form Type | 8-K |
| Filed Date | Feb 14, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: BCPC
TL;DR
BCPC shuffled execs and board members, effective Feb 12, 2025.
AI Summary
On February 12, 2025, Balchem Corporation (BCPC) announced changes in its executive team and board of directors. The company elected new directors and appointed new officers, alongside adjustments to compensatory arrangements for certain executives. These changes are effective as of the reporting date.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and operational direction.
Key Players & Entities
- Balchem Corporation (company) — Registrant
- February 12, 2025 (date) — Date of earliest event reported
- Maryland (jurisdiction) — State of incorporation
- Montvale, NJ (location) — Principal executive offices
FAQ
What specific roles were affected by the executive and director changes?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but does not specify the exact roles within this summary.
When were these changes effective?
The earliest event reported is dated February 12, 2025.
What is Balchem Corporation's state of incorporation?
Balchem Corporation is incorporated in Maryland.
Where are Balchem Corporation's principal executive offices located?
Balchem Corporation's principal executive offices are located at 5 Paragon Drive, Montvale, NJ 07645.
What SEC Act governs this filing?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 17.8 · Accepted 2025-02-14 16:18:18
Filing Documents
- ef20043682_8k.htm (8-K) — 29KB
- ef20043682_ex10-1.htm (EX-10.1) — 80KB
- 0001140361-25-004806.txt ( ) — 257KB
- bcpc-20250212.xsd (EX-101.SCH) — 4KB
- bcpc-20250212_lab.xml (EX-101.LAB) — 21KB
- bcpc-20250212_pre.xml (EX-101.PRE) — 16KB
- ef20043682_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 12, 2025, the Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Balchem Corporation (the "Company") approved the adoption of the Balchem Corporation Executive Severance Policy (the "Policy"). Eligible participants in this Policy ("Participants") are those employees who are designated by the Board as executive officers for purposes of the Securities Exchange Act of 1934, as amended. Pursuant to the Policy, in the event the Company or its subsidiaries terminates the employment of a Participant without Cause outside of a Change in Control Period (such terms as defined in the Policy) and such Participant has been employed by the Company for at least one year prior to such termination, then (1) such Participant is entitled to receive cash severance in an amount equal to the sum of a specified multiple of such Participant's base salary plus a specified multiple of such Participant's target annual bonus opportunity and COBRA coverage at the Company's expense for the length of the severance period set forth in the Policy (or earlier if benefits are provided by a new employer); and (2) such Participant's outstanding equity awards will be treated in accordance with the relevant equity award agreement. Further, subject to the terms and conditions of the Policy, in the event a Participant incurs an Involuntary Termination within a Change in Control Period (such terms as defined in the Policy), then (1) such Participant is entitled to receive cash severance in an amount equal to the sum of a specified multiple of such Participant's base salary plus a specified multiple of such Participant's target annual bonus opportunity and COBRA coverage at the Company's expense for the length of the severance period set forth in the Policy (or earlier if benefits are provided by a new empl
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Balchem Corporation Executive Severance Policy 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BALCHEM CORPORATION (Registrant) By: /s/ Hatsuki Miyata Hatsuki Miyata Executive Vice President, Chief Legal Officer and Secretary Date: February 14, 2025